Medical metaverse company apoQlar receives FDA 510(k) clearance for its…

apoQlar GmbH

Hamburg, Germany, April 20 /PRNewswire/

apoQlar, a German medical technology company, today announced that it has received 510(k) Class II clearance from the FDA for VSI HoloMedicine®, a breakthrough mixed reality medical software that enables surgeons to visualize complex procedures at using immersive Plan 3D holographic technology. With this approval, the United States becomes the 30th country in the VSI HoloMedicine® has received approval as a medical device. apoQlar will provide U.S. clinical distribution of VSI HoloMedicine® through its subsidiary in Miami, Florida, with expected availability in the second quarter of 2023.

After this great success, apoQlar is now raising funds in a Series A funding round, its first-ever fundraising campaign, to establish VSI Holomedicine® as the foundation of modern surgical care.

“With mixed reality, we are no longer tied to physical objects in a physical world. We can stack digital objects and services on top of the real world to deliver equal or greater value, often at a fraction of the cost. Mixed reality is a whole new way for people, in our case for surgeons, doctors and technologists, to continue to experience the real world around them, but with a whole virtual layer added,” says Sirko Pelzl, co-founder and CEO of apoQlar.

Using 3D holographic technology, VSI HoloMedicine® provides surgeons with a near “x-ray” perspective when planning surgery. Physicians in all medical fields can now plan surgeries in 3D and visualize medical data inside or outside the operating room. With Microsoft’s HoloLens 2, a mixed-reality head-mounted display (HMD), surgeons can transform two-dimensional CT, angio-CT, MRI, CBCT, PET, and SPECT sources into interactive 3D holograms. Sirko continues, “We are thrilled to finally be able to offer VSI HoloMedicine® to improve surgical outcomes for patients and provide surgeons with sophisticated surgical planning tools that improve their entire planning process. »

“FDA approval is an important milestone for us. We are a young company, but this is a real testament to the mindset and hard work of our team,” says Liliana Duarte, COO of apoQlar. This is the latest success for apoQlar in its global expansion plan and gives the company momentum for the coming year further market expansion in Southeast Asia, India and the states of the Gulf Coast.

Please visit or to learn more.

Information about apoQlar

apoQlar was founded in Hamburg in 2017 to bring a new perspective to healthcare. apoQlar has developed a cost-effective medical metaverse technology, VSI HoloMedicine®, to extend surgical planning, remote consultation, patient education and medical education to the crucial third dimension. VSI HoloMedicine® is FDA 510(k), CE Class I and HSA Class A certified for clinical use in 30 countries. The full description of the intended use of VSI HoloMedicine ® can be found here.

If you would like more information about VSI HoloMedicine® or would like to learn more about apoQlar’s Series A funding round, please contact


Andrew Fesler +1 954-675-4373
Photo –
Logo –
View original content: – vsi-holomedicine-301692387.html

Original content by: apoQlar GmbH, transmitted by news aktuell

Leave a Comment